PortalPublikationenDNA methylation profiling identifies two distinct subgroups ...

DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status

Standard

DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status. / Jurmeister, Philipp; Weber, Karsten; Villegas, Sonia; Karn, Thomas; Untch, Michael; Thieme, Anne; Müller, Volkmar; Taube, Eliane; Fasching, Peter; Schmitt, Wolfgang D; Marmé, Frederik; Stickeler, Elmar; Sinn, Bruno V; Jank, Paul; Schem, Christian; Klauschen, Frederick; van Mackelenbergh, Marion; Denkert, Carsten; Loibl, Sibylle; Capper, David.

in: CLIN EPIGENETICS, Jahrgang 13, Nr. 1, 184, 03.10.2021.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Jurmeister, P, Weber, K, Villegas, S, Karn, T, Untch, M, Thieme, A, Müller, V, Taube, E, Fasching, P, Schmitt, WD, Marmé, F, Stickeler, E, Sinn, BV, Jank, P, Schem, C, Klauschen, F, van Mackelenbergh, M, Denkert, C, Loibl, S & Capper, D 2021, 'DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status', CLIN EPIGENETICS, Jg. 13, Nr. 1, 184. https://doi.org/10.1186/s13148-021-01176-5

APA

Jurmeister, P., Weber, K., Villegas, S., Karn, T., Untch, M., Thieme, A., Müller, V., Taube, E., Fasching, P., Schmitt, W. D., Marmé, F., Stickeler, E., Sinn, B. V., Jank, P., Schem, C., Klauschen, F., van Mackelenbergh, M., Denkert, C., Loibl, S., & Capper, D. (2021). DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status. CLIN EPIGENETICS, 13(1), [184]. https://doi.org/10.1186/s13148-021-01176-5

Vancouver

Jurmeister P, Weber K, Villegas S, Karn T, Untch M, Thieme A et al. DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status. CLIN EPIGENETICS. 2021 Okt 3;13(1). 184. https://doi.org/10.1186/s13148-021-01176-5

Bibtex

@article{16072d6b2a514424a78d5ce166a021ec,
title = "DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status",
abstract = "BACKGROUND: Current clinical guidelines suggest that breast cancers with low hormone receptor expression (LowHR) in 1-10% of tumor cells should be regarded as hormone receptor positive. However, clinical data show that these patients have worse outcome compared to patients with hormone receptor expression above 10%. We performed DNA methylation profiling on 23 LowHR breast cancer specimens, including 13 samples with HER2 amplification and compared our results with a reference breast cancer cohort from The Cancer Genome Atlas to clarify the status for this infrequent but important patient subgroup.RESULTS: In unsupervised clustering and dimensionality reduction, breast cancers with low hormone receptor expression that lacked HER2 amplification usually clustered with triple negative breast cancer (TNBC) reference samples (8/10; {"}LowHR TNBC-like{"}). In contrast, most specimens with low hormone receptor expression and HER2 amplification grouped with hormone receptor positive cancers (11/13; {"}LowHR HRpos-like{"}). We observed highly similar DNA methylation patterns of LowHR TNBC-like samples and true TNBCs. Furthermore, the Ki67 proliferation index of LowHR TNBC-like samples and clinical outcome parameters were more similar to TNBCs and differed from LowHR HRpos-like cases.CONCLUSIONS: We here demonstrate that LowHR breast cancer comprises two epigenetically distinct groups. Our data strongly suggest that LowHR TNBC-like samples are molecularly, histologically and clinically closely related to TNBC, while LowHR HRpos-like specimens are closely related to hormone receptor positive tumors.",
author = "Philipp Jurmeister and Karsten Weber and Sonia Villegas and Thomas Karn and Michael Untch and Anne Thieme and Volkmar M{\"u}ller and Eliane Taube and Peter Fasching and Schmitt, {Wolfgang D} and Frederik Marm{\'e} and Elmar Stickeler and Sinn, {Bruno V} and Paul Jank and Christian Schem and Frederick Klauschen and {van Mackelenbergh}, Marion and Carsten Denkert and Sibylle Loibl and David Capper",
note = "{\textcopyright} 2021. The Author(s).",
year = "2021",
month = oct,
day = "3",
doi = "10.1186/s13148-021-01176-5",
language = "English",
volume = "13",
journal = "CLIN EPIGENETICS",
issn = "1868-7075",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status

AU - Jurmeister, Philipp

AU - Weber, Karsten

AU - Villegas, Sonia

AU - Karn, Thomas

AU - Untch, Michael

AU - Thieme, Anne

AU - Müller, Volkmar

AU - Taube, Eliane

AU - Fasching, Peter

AU - Schmitt, Wolfgang D

AU - Marmé, Frederik

AU - Stickeler, Elmar

AU - Sinn, Bruno V

AU - Jank, Paul

AU - Schem, Christian

AU - Klauschen, Frederick

AU - van Mackelenbergh, Marion

AU - Denkert, Carsten

AU - Loibl, Sibylle

AU - Capper, David

N1 - © 2021. The Author(s).

PY - 2021/10/3

Y1 - 2021/10/3

N2 - BACKGROUND: Current clinical guidelines suggest that breast cancers with low hormone receptor expression (LowHR) in 1-10% of tumor cells should be regarded as hormone receptor positive. However, clinical data show that these patients have worse outcome compared to patients with hormone receptor expression above 10%. We performed DNA methylation profiling on 23 LowHR breast cancer specimens, including 13 samples with HER2 amplification and compared our results with a reference breast cancer cohort from The Cancer Genome Atlas to clarify the status for this infrequent but important patient subgroup.RESULTS: In unsupervised clustering and dimensionality reduction, breast cancers with low hormone receptor expression that lacked HER2 amplification usually clustered with triple negative breast cancer (TNBC) reference samples (8/10; "LowHR TNBC-like"). In contrast, most specimens with low hormone receptor expression and HER2 amplification grouped with hormone receptor positive cancers (11/13; "LowHR HRpos-like"). We observed highly similar DNA methylation patterns of LowHR TNBC-like samples and true TNBCs. Furthermore, the Ki67 proliferation index of LowHR TNBC-like samples and clinical outcome parameters were more similar to TNBCs and differed from LowHR HRpos-like cases.CONCLUSIONS: We here demonstrate that LowHR breast cancer comprises two epigenetically distinct groups. Our data strongly suggest that LowHR TNBC-like samples are molecularly, histologically and clinically closely related to TNBC, while LowHR HRpos-like specimens are closely related to hormone receptor positive tumors.

AB - BACKGROUND: Current clinical guidelines suggest that breast cancers with low hormone receptor expression (LowHR) in 1-10% of tumor cells should be regarded as hormone receptor positive. However, clinical data show that these patients have worse outcome compared to patients with hormone receptor expression above 10%. We performed DNA methylation profiling on 23 LowHR breast cancer specimens, including 13 samples with HER2 amplification and compared our results with a reference breast cancer cohort from The Cancer Genome Atlas to clarify the status for this infrequent but important patient subgroup.RESULTS: In unsupervised clustering and dimensionality reduction, breast cancers with low hormone receptor expression that lacked HER2 amplification usually clustered with triple negative breast cancer (TNBC) reference samples (8/10; "LowHR TNBC-like"). In contrast, most specimens with low hormone receptor expression and HER2 amplification grouped with hormone receptor positive cancers (11/13; "LowHR HRpos-like"). We observed highly similar DNA methylation patterns of LowHR TNBC-like samples and true TNBCs. Furthermore, the Ki67 proliferation index of LowHR TNBC-like samples and clinical outcome parameters were more similar to TNBCs and differed from LowHR HRpos-like cases.CONCLUSIONS: We here demonstrate that LowHR breast cancer comprises two epigenetically distinct groups. Our data strongly suggest that LowHR TNBC-like samples are molecularly, histologically and clinically closely related to TNBC, while LowHR HRpos-like specimens are closely related to hormone receptor positive tumors.

U2 - 10.1186/s13148-021-01176-5

DO - 10.1186/s13148-021-01176-5

M3 - SCORING: Journal article

C2 - 34602069

VL - 13

JO - CLIN EPIGENETICS

JF - CLIN EPIGENETICS

SN - 1868-7075

IS - 1

M1 - 184

ER -